Purified anti-β-Amyloid, 1-40 Antibody (Prev
- 产品名称：
- Purified anti-β-Amyloid, 1-40 Antibody (Prev
- 产品编号：
- 805409
- 产品类别：
- 牛ELISA试剂盒
- 检测样本：
- 805409
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Formulation
- Phosphate-buffered solution (no preservatives or carrier proteins).
- Preparation
- The antibody was purified by affinity chromatography.
- Concentration
- 0.5 mg/ml
- Storage & Handling
- Do not store antibody diluted below 50 ?g/mL in the absence of protein (i.e.: add 2% bovine serum albumin). The antibody solution should be stored undiluted between 2°C and 8°C. Please note the storage condition for this antibody has been changed from -20°C to between 2°C and 8°C. You can also check your vial or your CoA to find the most accurate storage condition for this antibody.
- Application
-
IHC-P -?Quality tested
DOT Blot, ELISA - Reported in the literature, not verified in house
- Recommended Usage
Each lot of this antibody is quality control tested by formalin-fixed paraffin-embedded immunohistochemical staining. For immunohistochemistry, a concentration range of 5.0 - 10 ?g/ml is suggested. It is recommended that the reagent be titrated for optimal performance for each application.
- Application Notes
Clone 11A50-B10 is reactive to the C-terminus of beta amyloid and is specific for the isoform ending at the 40th amino acid.
- Application References
(PubMed link indicates BioLegend citation) -
- Watts JC, et al. 2014. Proc. Natl. Sci. USA 28:10323. (IHC-P) PubMed
- Diomede L, et al. 2014. Neurobiol. Dis. 62:521. (Dot Plot) PubMed
- Watanabe H, et al. 2012. J Neurosci. 15:5085. (ELISA) PubMed
- Portelius E, et al. 2006. J. Proteome Res. 4:1010. (IP)
- Vingtdeux V, et al. 2011. FASEB J. 25:219. (ELISA) PubMed
- Ohmi K, et al. 2011. PLoS One 11:e27461. (IHC-Other) PubMed
- Product Citations
-
- Vingtdeux V, et al. 2011. FASEB J. 25:219-231. PubMed
- Watts J, et al. 2014. Proc Natl Acad Sci U S A. 111:10323-10328. PubMed
- Lisa Dolfe et al. 2018. Journal of Alzheimer's disease reports. 2(1):27-39 . PubMed
- Diomede L, et al. 2014. Neurobiol Dis. 62:521-532. PubMed
- Watanabe H, et al. 2012. J Neurosci. 32:5085-5096. PubMed
- Voth S, et al. 2020. FASEB J. 9156:34. PubMed
- Shi H, et al. 2020. Acta Neuropathol. 139:813. PubMed
- Bourassa P, et al. 2020. Neuropathol Appl Neurobiol. 46:458. PubMed
- Plowey ED, et al. 2022. Acta Neuropathol. 144:143. PubMed
- Lee CYD et al. 2018. Neuron. 97(5):1032-1048 . PubMed
- Kim K, et al. 2020. Nat Commun. 0.540972222. PubMed
- Shi H, et al. 2020. Acta Neuropathol Commun. 0.473611111. PubMed
- Ohmi K, et al. 2011. PLoS One. 6:e27461. PubMed
- Parker H, et al. 2020. EMBO Mol Med. 12:e11185. PubMed
- Ruiz–Riquelme A, et al. 2018. Acta Neuropathol Commun. 6:26. PubMed
- Carreras I, et al. 2019. Sci Rep. 9:10972. PubMed
- RRID
- AB_2734555 (BioLegend Cat. No. 805409) AB_2564680 (BioLegend Cat. No. 805401) AB_2564681 (BioLegend Cat. No. 805402) AB_2564679 (BioLegend Cat. No. 805403)
